CPSE:NOVO BPharmaceuticals
Assessing Novo Nordisk’s Valuation After Recent Share Price Weakness
Recent share performance and business snapshot
Novo Nordisk (CPSE:NOVO B) has been under pressure, with the share price showing a 1 day decline of about 1% and negative returns over the past week, month and past 3 months.
Despite this weaker recent performance, the company reports annual revenue of DKK 309.1b and net income of DKK 102.4b. Most of this comes from its Diabetes and Obesity Care segment, supported by a smaller Rare Disease business.
See our latest analysis for Novo Nordisk.
At...